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Abstract
Background: Metabolic syndrome (MetS) has been reported as a risk factor for cardiovas-
cular events. The aim of the present study is to investigate the association between chronic 
angiotensin-converting enzyme inhibitors (ACE-I) therapy and the rate of periprocedural 
myocardial infarction (PMI) after elective coronary stenting among patients with MetS.
Methods: The inclusion criteria were MetS and plan for elective percutaneous coronary in-
tervention. To assess the effect of ACE-I treatment on the incidence of PMI, measurements of 
cardiac biomarkers (CK-MB mass and troponin I) were performed at baseline and 24 h after 
the procedure.
Results: A total of 459 patients fulfilling the inclusion criteria were recruited to chronic ACE-I  
treatment and ACE-I naive groups in a 2/1 ratio. Baseline troponin I and CK-MB levels were 
similar in both treatment groups, whereas they were significantly lower in ACE-I group 24 h 
after the procedure. Univariate analysis identified body mass index (BMI), LDL cholesterol, 
nitrate and ACE-I use as significant factors for the development of PMI. Multivariate regres-
sion model revealed that body mass index increased and use of nitrate and ACE-I decreased 
the probability of PMI independent from confounding factors (OR 1.14, 95% CI 1.05–1.23,  
p = 0.002 for BMI; OR 0.26, 95% CI 0.14–0.48, p = 0.01 for nitrate use, OR 0.51, 95% CI 
0.27–0.93, p = 0.03 for ACE-I use).
Conclusions: This prospective observational cohort trial demonstrated that chronic ACE-I 
therapy was an independent predictor for reduced PMI among patients with MetS who under-
went elective coronary intervention. (Cardiol J 2015; 22, 3: 323–329)
Key words: angiotensin converting enzyme inhibitor, coronary artery disease, 
metabolic syndrome, percutaneous coronary intervention, periprocedural  
myocardial infarction
Introduction
The metabolic syndrome (MetS) is a constel-
lation of risk factors including central obesity, 
insulin resistance, dyslipidemia, hypertension 
and impaired glucose tolerance, which are highly 
associated with increased mortality and morbid-
ity of cardiovascular diseases [1–3]. Although the 
pathogenesis of MetS remains unclear, abdominal 
obesity and insulin resistance have been suggested 
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to be the underlying feature [4]. Patients with MetS 
have increased incidence of adverse cardiovascu-
lar events compared to those without MetS after 
coronary stent implantation [5].
Periprocedural myocardial infarction (PMI) oc-
curs in up to 5–30% of patients after percutaneous 
coronary interventions (PCI) [6, 7] and predicts 
adverse events and prognosis even after apparently 
successful procedures [8, 9].
Angiotensin-converting enzyme inhibitors 
(ACE-I) have favorable effects on insulin resistance 
[10], endothelial functions [11] and atherosclerosis 
[12, 13]. Whether ACE-I therapy can also protect 
patients with MetS before elective coronary stent-
ing remains unknown.
On the basis of these data, we hypothesized 
that chronic ACE-I therapy before elective coro-
nary interventions might reduce the incidence of 
PMI among patients with MetS.
Methods
An observational prospective cohort study 
was designed to determine whether chronic ACE-I 
treatment reduces the rate of PMI among patients 
with MetS. All consecutive patients scheduled 
for elective coronary stenting between February 
and June 2014 were screened for eligibility. The 
inclusion criteria were MetS and plan for elective 
percutaneous coronary stenting.
MetS was defined according to the third report 
of the National Cholesterol Education Program Ex-
pert Panel on detection, evaluation and treatment 
of high blood cholesterol in adults (ATP-III), as the 
presence of 3 or more of these components: high 
fasting glucose (fasting serum glucose ≥ 100 mg/dL 
or drug treatment for elevated blood glucose), 
abdominal obesity (given as waist circumference 
> 102 cm in men and > 88 cm in women), high 
blood pressure (≥ 130/≥ 85 mm Hg or drug treat-
ment for hypertension), hypertriglyceridemia 
(serum triglycerides ≥ 150 mg/dL), and low high-
density lipoprotein cholesterol (< 40 mg/dL in men 
and < 50 mg/dL in women) [10]. Patients were 
excluded if they had acute coronary events, kidney 
failure (creatinine > 2 mg/dL), left main coro-
nary artery disease, chronic total occlusion, any 
contraindication of aspirin, clopidogrel or ACE-I 
treatment, increased levels of baseline creatine 
kinase-myocardial band (CK-MB) and/or troponin I, 
were on ACE-I < 1 month or on angiotensin recep-
tor blocker therapy, needed the use of glycoprotein 
IIb/IIIa antagonists (Fig. 1).
All patients provided their written, infor- 
med consents. This study was approved by the 
institutional committee on human research 
and registered at ClinicalTrials.gov (identifier: 
NCT02054390).
We presumed an 18% incidence of primary 
endpoints according to the previous studies in 
Figure 1. Flow diagram of patients. The diagram includes detailed information on the excluded patients; ACE-I — 
angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; CK-MB — creatine kinase myocardial 
band; MetS — metabolic syndrome; PMI — periprocedural myocardial infarction.
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the control group and prospectively decided on 
an allocation ratio of 2/1. The total sample size of 
410 patients would provide 80% power to detect 
50% reduction of the rate in patients who received 
ACE-I with an alpha level of 0.05. We recruited 
459 patients with MetS, of which 306 were under 
chronic ACE-I, and 153 were ACE-I naive.
The chronic ACE-I use was defined as more 
than 1 month of ACE-I treatment. Types of ACE-I 
used were ramipril (n = 135), perindopril (n = 96), 
lisinopril (n = 59) and trandolapril (n = 16). All 
patients received 300 mg of clopidogrel as a loading 
dose at least 12 h before the procedure and 75 mg/d 
maintenance dose thereafter. During the interven-
tion, an intravenous bolus of weight-adjusted unfrac-
tionated heparin with a targeted activated clotting 
time of 250–300 s was administered. Extra pre- or 
post-dilatation with a balloon, or intracoronary 
nitrate administration for maximal epicardial vaso-
dilation were left at the discretion of the operator. 
As a final step, stenting was performed.
To assess the effect of ACE-I treatment on 
the incidence of PMI, measurements of cardiac 
biomarkers were performed at baseline and 24 h 
after the procedure. CK-MB and troponin I were 
measured by chemiluminescence immunoassays 
on automated analyzers (Access, Beckman Coulter, 
Fullerton, CA). The upper limits of normal (ULN) 
were defined as the 99th percentile of the normal 
population according to the European Society of 
Cardiology/American College of Cardiology Founda-
tion/American Heart Association/World Heart Fe-
deration universal definition [14]. Laboratory ULN 
was 6.3 ng/mL for CK-MB mass and 0.04 ng/mL 
for troponin I. The primary outcome measure was 
PMI that was defined as cardiac troponin I release 
of > 5 times ULN 24 h after PCI. The secondary 
outcome measure was periprocedural myocardial 
injury that was defined as cardiac troponin I release 
of > 1 × ULN 24 h after PCI. The operators who 
performed the stenting procedure and the labora-
tory staff who measured cardiac biomarkers were 
blinded to treatment groups.
Statistical analysis
All analyses were performed using an SPSS 
software package (version 20 for Windows, SPSS 
Inc., Chicago, IL). Data are expressed as frequen-
cies and percentages for discrete variables and 
as means ± standard deviation for continuous 
variables. Distributions of data were assessed by 
the Shapiro-Wilk test. Continuous variables were 
compared by Student’s unpaired t-test or Mann-
-Whitney U-test according to the distribution of 
data. The c2 analysis or Fisher’s exact test was 
used to assess the significance of differences 
between dichotomous variables. In univariate 
logistic regression analysis; age, sex, body mass 
index, presentation of hypertension, diabetes, 
family history of coronary artery disease, history 
of myocardial infarction, serum creatinine level, 
plasma levels of total cholesterol, low- and high-
-density lipoprotein and triglyceride before the 
procedure, use of statins, beta-blockers, calcium 
channel blockers, nitrates, angiographic and pro-
cedural variables including the lesion morphology, 
a multivessel intervention, use of drug-eluting 
stents, total stent length, stent diameter, number 
of implanted stents, maximum balloon inflation 
time, maximum balloon inflation pressure and 
treatment assignment were assessed. Univaria-
te correlates of periprocedural infarction with 
a p value < 0.1 plus terms for age and gender (due 
to their well-established association with heart 
disease) were included in the multiple logistic 
regression analyses for odds ratios (OR) and 95% 
confidence intervals (CI). Results with a p value 
< 0.05 were considered significant.
Results
Among 1,275 patients screened for the study, 
816 patients were excluded for various reasons 
(Fig. 1). Therefore, a total of 459 patients fulfilling 
the inclusion criteria were recruited to chronic 
ACE-I treatment and ACE-I naive groups in 
a 2/1 ratio. Comparisons of different demographic, 
clinical and angiographic characteristics are shown 
in Table 1. Participants were mainly male (74%) 
with a mean age of 61 years. The patients in the 
ACE-I group had a trend toward higher baseline 
prevalence of hypertension (p = 0.09), diabetes 
mellitus (p = 0.07) and previous myocardial infarc-
tion (p = 0.07). The number of stents implanted 
per patient tended to be higher in ACE-I treatment 
group (p = 0.06).
None of the patients died in the hospital. All 
patients enrolled in the study underwent successful 
stent implantation. The overall rate of the primary 
outcome, defined as cardiac troponin I release 
of > 5 times ULN 24 h after PCI was 7.4% 
(34 patients) among the whole population. The in-
cidence of periprocedural myocardial injury, which 
is the secondary outcome measure was 18.5% 
(85 patients). Troponin I levels were significantly cor-
related with CK-MB levels 24 h after PCI (r = 0.54, 
p < 0.01). Baseline troponin I and CK-MB levels 
were similar in both treatment groups, whereas 
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Table 2. Myocardial necrosis markers at baseline and 24 hours after the procedure.
Biomarker: Median (IQR) [ng/mL] ACE-I group (n = 306) ACE-I naive group (n = 153) P
Baseline troponin I 0.02 (0.02–0.03) 0.02 (0.02–0.03) 0.69
Baseline CK-MB 3.3 (1.7–4.0) 3.4 (1.7–4.0) 0.64
Troponin I at 24 h 0.03 (0.02–0.03) 0.04 (0.03–0.04) 0.03
CK-MB at 24 h 4.1 (2.3–5.8) 5.7 (3.8–6.2) 0.04
ACE-I — angiotensin converting enzyme inhibitor; CK-MB — creatinine kinase myocardial band; IQR — interquartile range
biomarkers were significantly lower in ACE-I 
group 24 h after the procedure, indicating that 
more protection was conferred by ACE-I treatment 
(Table 2). Rates of PMI and injury are shown in 
Figure 2. Chronic ACE-I therapy provided 5.5% 
of absolute risk reduction (ARR) and 49.5% of 
relative risk reduction (RRR) for PMI. Benefits of 
ACE-I on secondary outcome measure were 8.5% 
Table 1. Baseline demographic, clinical and angiographic characteristics of patients.
Characteristics ACE-I group (n = 306) ACE-I naive group (n = 153) P
Age [years] 61.6 ± 9.8 59.9 ± 9.5 0.09
Male sex 223 (72.9%) 115 (75.2%) 0.65
Hypertension 241 (78.8%) 109 (71.2%) 0.09
Diabetes mellitus 124 (40.5%) 55 (35.9%) 0.07
Family history of CAD 114 (37.3%) 59 (38.6%) 0.82
Current smoker 120 (39.2%) 70 (45.7%) 0.19
Fasting blood glucose [mg/dL] 133.5 ± 62.2 128.1 ± 58.6 0.48
Creatinine [mg/dL] 1.02 ± 0.33 1.09 ± 0.36 0.28
Total cholesterol [mg/dL] 177.8 ± 51.0 184.3 ± 54.1 0.25
LDL cholesterol [mg/dL] 102.9 ± 37.2 106.8 ± 45.8 0.38
HDL cholesterol [mg/dL] 41.8 ± 10.2 40.4 ± 9.8 0.47
Triglyceride [mg/dL] 179.6 ± 103.4 194.4 ± 107.6 0.22
Previous MI 116 (37.9%) 45 (29.4%) 0.07
Previous CABG 46 (15%) 17 (11.1%) 0.26
LVEF [%] 61 ± 11 62 ± 11 0.58
Beta-blockers 226 (73.9%) 105 (68.6%) 0.23
Statins 264 (86.3%) 122 (79.7%) 0.08
Nitrate 178 (58.2%) 85 (55.6%) 0.56
Calcium channel blockers 20 (6.5%) 13 (8.5%) 0.44
Multivessel intervention 89 (29.1%) 34 (22.2%) 0.36
Lesion type B2/C 115 (37.6%) 54 (35.3%) 0.88
Number of stents per patient 1.7 ± 0.9 1.5 ± 0.8 0.06
Number of DES per patient 0.54 ± 0.34 0.47 ± 0.38 0.44
LAD artery 152 (49.7%) 69 (45.1%) 0.33
Saphenous graft 6 (2%) 3 (2%) 0.88
Length of stent [mm] 21.4 ± 11.4 18.4 ± 8.1 0.10
Diameter of stent [mm] 2.9 ± 0.4 2.9 ± 0.4 0.84
Side branch occlusion 17 (5.6%) 8 (5.3%) 0.76
ACE-I — angiotensin converting enzyme inhibitor; CABG — coronary artery bypass graft; CAD — coronary artery disease, DES — drug eluting 
stent, HDL — high density lipoprotein; LAD — left anterior descending; LDL — low density lipoprotein; LVEF — left ventricular ejection fraction; 
MI —myocardial infarction
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for ARR and 35.2% for RRR (Fig. 2). Increase in 
frequency of PMI in the ACE-I naive group also 
translated to an increase in the length of hospital 
stay (3.5 ± 1.2 vs. 2.0 ± 0.6 days among patients 
with and without PMI, respectively, p < 0.001). 
Patients in the ACE-I group had shorter duration 
of hospital stay than those in the ACE-I naive 
group (1.9 ± 0.7 vs. 2.2 ± 0.9 days, respectively, 
p = 0.03). The influence of ACE-I therapy on PMI 
was examined by comparing the hazard ratio of 
various factors described previously. Univariate 
analysis identified body mass index, low density 
lipoprotein cholesterol, nitrate and ACE-I use as 
significant factors for the development of PMI. 
Multivariate regression model revealed that body 
mass index increased and use of nitrate and ACE-I 
decreased the probability of PMI independent from 
confounding factors (OR 1.14, 95% CI 1.05–1.23, 
p = 0.002 for body mass index, OR 0.26, 95% CI 
0.14–0.48, p = 0.01 for nitrate use, OR 0.51, 95% 
CI 0.27–0.93, p = 0.03 for ACE-I use) (Table 3). 
No difference was observed in the incidence of 
PMI between various ACE-I drugs (Table 4). Four 
(1.3%) patients reached the maximal dose of ACE-I 
and 205 (67%) patients reached the at least 50% of 
maximal dose of ACE-I.
Discussion
The current prospective cohort study demon-
strated a lower risk of PMI among patients with 
MetS, who were under chronic ACE-I therapy (OR 
0.51, 95% CI 0.27–0.93). Significant decreases 
in the incidences of both PMI and injury were 
provided by ACE-I treatment (p = 0.032 and 
p = 0.027, respectively).
Existing studies have yielded inconsistent data 
on whether MetS increases the risk of cardiovas-
cular events after PCI [15–18]. However, a recent 
meta-analysis stated MetS as an important risk 
factor following stent implantation [5].
Renin–angiotensin system is regulated by 
hyperlipidemia, hyperglycemia and obesity, which 
are components of MetS and it is also a therapeutic 
target for several risk factors associated with MetS 
[19]. Although the data from the clinical studies are 
limited, ACE-I are known to have favorable effects 
on patients with MetS [20, 21]. Their effects on 
PMI were not assessed. Therefore, we sought to 
determine whether ACE-I therapy prevents PMI 
among patients with MetS, who underwent elective 
coronary stenting.
ACE-I therapy is known to be beneficial in 
patients with coronary atherosclerotic disease [22, 
23]. The cardioprotective effects of intracoronary 
ACE-I therapy during coronary angioplasty were 
described previously among patients with stable 
coronary artery disease [24] and acute myocardial 
infarction [25]. The favorable effects of ACE-I may 
be due to increased endogenous bradykinin activity 
which mediates improvement of the endothelium-
dependent epicardial vasomotion [26]. ACE-I were 
also shown to improve coronary microvascular 
functions and protect the myocardium from the 
procedure-related injury during PCI [24, 27]. Our 
data extended these previous findings by demon-
strating that treatment with ACE-I therapy before 
PCI was associated with a lower incidence of PMI, 
defined as the elevation of troponin I or CK-MB 
values > 5 times ULN, among patients with MetS.
PCI may cause PMI by formation of distal 
microembolization and induction of reperfusion 
injury of the ischemic myocardium. PMI is as-
sociated with adverse events and poor prognosis. 
Several risk factors are associated with PMI and 
include patient characteristics, lesion related 
and procedure-related factors [28]. Rates of hy-
pertension, diabetes mellitus, prior myocardial 
infarction and number of stents per patient were 
insignificantly higher among patients under chronic 
ACE-I treatment. First three of these risk factors 
Figure 2. Comparisons of incidences of periprocedural 
myocardial infarction, defined as increase in troponin I 
and creatinine kinase myocardial band (CK-MB) 5 times 
the upper normal limit, and periprocedural myocar-
dial injury, defined as increase in troponin I and CK-MB 
above the upper normal limit between the chronic an-
giotensin converting enzyme inhibitor (ACE-I; n = 306) 
and ACE-I naive (n = 153) groups; ULN — upper limit 
normal.
www.cardiologyjournal.org 327
Ozgur Ulas Ozcan et al., ACE inhibitors in metabolic syndrome
Table 3. Univariate and multivariate logistic regression analyses for periprocedural myocardial infarction.
Variable Univariate Multivariate
Odds ratio 95% CI P Odds ratio 95% CI P
Age 1.01 0.98–1.05 0.47 0.98 0.95–1.01 0.22
Female 1.46 0.63–3.38 0.38 1.21 0.58–2.52 0.61
Body mass index 1.29 1.02–1.77 0.007 1.14 1.05–1.23 0.002
Hypertension 0.96 0.42–2.20 0.92
Diabetes mellitus 0.90 0.54–1.50 0.69
Family history 0.91 0.47–1.79 0.79
Current smoker 0.89 0.55–1.44 0.64
History of MI 1.19 0.58–2.45 0.63
Creatinine 1.05 0.56–1.97 0.87
Total cholesterol 1.01 0.98–1.03 0.49
HDL cholesterol 0.99 0.97–1.02 0.67
LDL cholesterol 1.03 1.01–1.05 0.04 0.99 0.99–1.01 0.69
Triglyceride 0.99 0.99–1.01 0.58
Statin 0.65 0.35–1.32 0.09 0.84 0.37–1.91 0.68
Beta-blocker 1.35 0.79–2.38 0.16
CCB 2.01 0.65–6.44 0.22
Nitrate 0.49 0.24–0.88 0.03 0.26 0.14–0.48 0.01
Lesion B2/C 1.21 0.86–1.89 0.06 1.20 0.67–2.20 0.53
Multivessel intervention 1.09 0.44–2.68 0.85
DES use 1.31 0.84–2.06 0.24
Stent length 1.01 0.96–1.06 0.72
Stent diameter 0.53 0.23–1.22 0.13
Number of stents 0.76 0.33–1.77 0.52
Balloon inflation time 1.06 0.93–1.16 0.42
Balloon inflation pressure 0.89 0.74–1.08 0.24
ACE-I use 0.48 0.23–0.87 0.02 0.51 0.27–0.93 0.03
ACE-I — angiotensin converting enzyme inhibitor; CCB — calcium channel blockers; CI — confidence interval; DES — drug-eluting stent;  
HDL — high density lipoprotein; CK-MB — creatinine kinase myocardial band; MI — myocardial infarction; LDL — low density lipoprotein
Table 4. Incidences of periprocedural myocardial injury and myocardial infarction according to the 
various types of angiotensin converting enzyme inhibitor drugs.
Ramipril  
(n = 135)
Perindopril  
(n = 96)
Lisinopril  
(n = 59)
Trandolapril  
(n = 16)
P
Troponin I > ULN 22 (16.3%) 13 (13.5%) 10 (16.9%) 3 (18.8%) 0.96
CK-MB > ULN 21 (15.6%) 13 (13.5%) 11 (18.6%) 4 (25%) 0.63
Troponin I > 5 × ULN 9 (6.7%) 4 (4.2%) 3 (5.1%) 1 (6.3%) 0.87
CK-MB > 5 × ULN 8 (5.9%) 4 (4.2%) 3 (5.1%) 1 (6.3%) 0.94
CK-MB — creatinine kinase myocardial band; ULN — upper limit normal
are patient-related risk factors, and the last one is 
procedure-related risk factor for PMI. Even the 
rates of these components tended to be higher 
among patients under ACE-I therapy, rate of PMI 
was observed lower in this group. Other patient 
characteristics, lesion related risk factors and 
procedural features were similar between ACE-I 
treatment and naive groups. Although investigating 
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the difference between various types of the ACE-I 
is beyond the scope of this trial, we noted no dif-
ference between 4 types of ACE-I. The positive 
effect of ACE-I may be considered a class effect.
Conclusions
There is little data in the literature suggesting 
that ACE-I given periprocedurally are cardioprotec-
tive. In conclusion, this prospective observational 
cohort study demonstrated that the chronic ACE-I 
therapy was an independent predictor for reduced 
PMI among patients with MetS who underwent 
elective coronary intervention. These results gen-
erate hypothesis if all patients with MetS should be 
on ACE-I therapy. Prospective randomized trials 
are needed to test this hypothesis.
Conflict of interest: None declared
References 
1.  Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. 
Lancet, 2005; 365: 1415–1428.
2.  Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity 
and mortality associated with the metabolic syndrome. Diabetes 
Care, 2001; 24: 683–689.
3.  Ford ES. The metabolic syndrome and mortality from cardiovas-
cular disease and all-causes: Findings from the National Health 
and Nutrition Examination Survey II Mortality Study. Athero-
sclerosis, 2004; 173: 309–314.
4.  Reaven G. The metabolic syndrome or the insulin resistance 
syndrome? Different names, different concepts, and different 
goals. Endocrinol Metabolism Clin North Am, 2004; 33: 283–303.
5.  Xu D, Guo Y, Wang H et al. The angiographic and clinical out-
comes after coronary stenting in patients with metabolic syn-
drome. Atherosclerosis, 2012; 221: 416–421.
6.  Califf RM, Abdelmeguid AE, Kuntz RE et al. Myonecrosis after re-
vascularization procedures. J Am Coll Cardiol, 1998; 31: 241–251.
7.  Pervaiz MH, Sood P, Sudhir K et al. Periprocedural myocar-
dial infarction in a randomized trial of everolimus-eluting and 
Paclitaxel-eluting coronary stents: Frequency and impact on 
mortality according to historic versus universal definitions. Circ 
Cardiovasc Interv, 2012; 5: 150–156.
8.  Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred 
by small elevations of creatine kinase-MB isoenzyme after per-
cutaneous coronary intervention. J Am Coll Cardiol, 2003; 42: 
1406–1411.
9.  Kini AS, Lee P, Marmur JD et al. Correlation of post percutaneous 
coronary intervention creatine kinase-MB and troponin I elevation 
in predicting mid-term mortality. Am J Cardiol, 2004; 93: 18–23.
10.  Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Lenfant C; 
American Heart Association, National Heart, Lung, Blood, Insti-
tute. Definition of metabolic syndrome: Report of the National 
Heart, Lung, and Blood Institute/American Heart Association 
conference on scientific issues related to definition. Circulation, 
2004; 109: 433–438.
11.  Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting 
enzyme inhibitors effect on endothelial dysfunction: A meta-
analysis of randomised controlled trials. Atherosclerosis, 2011; 
216: 7–16.
12.  McAlister FA, Renin-Angiotensin System Modulator Meta-Anal-
ysis I. Angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers are beneficial in normotensive atherosclerotic 
patients: A collaborative meta-analysis of randomized trials. Eur 
Heart J, 2012; 33: 505–514.
13.  Patarroyo Aponte MM, Francis GS. Effect of Angiotensin-con-
verting enzyme inhibitors and Angiotensin receptor antagonists 
in atherosclerosis prevention. Curr Cardiol Rep, 2012; 14: 433–
–442.
14.  Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, 
White HD. ESC Committee for Practice Guidelines (CPG). Third 
universal definition of myocardial infarction. Eur Heart J, 2012; 
33: 2551–2567.
15.  Rana JS, Monraats PS, Zwinderman AH et al. GENDER study. 
Metabolic syndrome and risk of restenosis in patients undergo-
ing percutaneous coronary intervention. Diabetes Care, 2005; 
28: 873–877.
16.  Kim JS, Lee HC, Choi BK et al. Impact of metabolic syndrome 
on in-stent restenosis and clinical outcomes after percutaneous 
coronary stent implantation. Diabetes Res Clin Pract, 2010; 88: 
e38–e41.
17.  Bin H, Yujie Z, Yuyang L et al. Impact of metabolic syndrome 
on clinical outcomes after drug-eluting stent implantation 
in patients with coronary artery disease. Angiology, 2011; 62: 
440–446.
18.  Hoffmann R, Stellbrink E, Schroder J et al. Impact of the metabol-
ic syndrome on angiographic and clinical events after coronary 
intervention using bare-metal or sirolimus-eluting stents. Am 
J Cardiol, 2007; 100: 1347–1352.
19.  Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-
angiotensin system: A target of and contributor to dyslipidemias, 
altered glucose homeostasis, and hypertension of the metabolic 
syndrome. Am J Physiol Heart and Circ Physiol, 2012; 302: 
H1219–1230.
20.  Khan BV, Sola S, Lauten WB et al. Quinapril, an ACE inhibitor, 
reduces markers of oxidative stress in the metabolic syndrome. 
Diabetes Care, 2004; 27: 1712–1715.
21.  Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilme-
nidine and lisinopril on ambulatory blood pressure and plasma 
lipid and glucose levels in hypertensive women with metabolic 
syndrome. Curr Med Res Opin, 2005; 21: 113–119.
22.  Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Ef-
fects of an angiotensin-converting-enzyme inhibitor, ramipril, on 
cardiovascular events in high-risk patients. The Heart Outcomes 
Prevention Evaluation Study Investigators. N Engl J Med, 2000; 
342: 145–153.
23.  Fox KM, Investigators EUtOrocewPiscAd. Efficacy of Perindopril 
in reduction of cardiovascular events among patients with stable 
coronary artery disease: Randomised, double-blind, placebo-
controlled, multicentre trial (the EUROPA study). Lancet, 2003; 
362: 782–788.
24.  Leesar MA, Jneid H, Tang XL, Bolli R. Pretreatment with intra-
coronary enalaprilat protects human myocardium during per-
cutaneous coronary angioplasty. J Am Coll Cardiol, 2007; 49: 
1607–1610.
25.  Schaefer U, Kurz T, Bonnemeier H et al. Intracoronary enal-
aprilat during angioplasty for acute myocardial infarction: Allevia-
tion of post-ischaemic neurohumoral and inflammatory stress? 
J Intern Med, 2007; 261: 188–200.
26.  Prasad A, Husain S, Quyyumi AA. Abnormal flow-mediated epi-
cardial vasomotion in human coronary arteries is improved by 
angiotensin-converting enzyme inhibition: A potential role of 
bradykinin. J Am Coll Cardiol, 1999; 33: 796–804.
27.  Mangiacapra F, Peace AJ, Di Serafino L et al. Intracoronary Enal-
aPrilat to Reduce MICROvascular Damage During Percutane-
ous Coronary Intervention (ProMicro) study. J Am Coll Cardiol, 
2013; 61: 615–621.
28.  Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur 
Heart J, 2005; 26: 2493–2519.
www.cardiologyjournal.org 329
Ozgur Ulas Ozcan et al., ACE inhibitors in metabolic syndrome
